Phthalazinone pyrazole |
Katalog-Nr.GC13668 |
Phthalazinonpyrazol ist ein potenter, selektiver und oral aktiver Inhibitor der Aurora-A-Kinase mit einem IC50 von 0,031 μM. Phthalazinonpyrazol kann die Mitose stoppen und anschließend das Tumorwachstum durch Apoptose proliferierender Zellen hemmen. Phthalazinonpyrazol unterdrÜckt die epithelial-mesenchymale Transition (EMT) wÄhrend der Differenzierung von hepatozytenÄhnlichen Zellen (HLCs) aus humanen embryonalen Stammzellen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 880487-62-7
Sample solution is provided at 25 µL, 10mM.
Phthalazinone pyrazole is potent, selective, and orally bioavailable inhibitor of Aurora-A kinase [1]. The Aurora protein kinase family consists of Aurora-A, -B and –C. The Aurora kinases are important group of enzymes involved in controlling several aspects of cell division in mammalian cells. Dysfunction of these kinases has been associated with a failure to maintain a stable chromosome content, a state that can contribute to tumourigenesis. Aurora-A is overexpressed in a variety of tumor types and displays oncogenic activity [2].
In vitro: Phthalazinone pyrazole potently inhibited the activity of Aurora A kinase with an IC50 of 31 nM. It showed no inhibitory effect on Aurora B kinase at doses up to 100 μM. Phthalazinone pyrazole inhibited the proliferation of HCT116, Colo205, and MCF-7 cells with IC50 values of 7.8, 2.9, and 1.6 μM, respectively [1].
References:
[1] Prime M E, Courtney S M, Brookfield F A, et al. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase[J]. Journal of medicinal chemistry, 2010, 54(1): 312-319.
[2] Vader G, Lens S M A. The Aurora kinase family in cell division and cancer[J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2008, 1786(1): 60-72.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *